Fi­bro­Gen grap­ples with PhI­II set­back in Duchenne mus­cu­lar dy­s­tro­phy

Fi­bro­Gen’s top an­ti­body can­di­date has failed a Phase III study in Duchenne mus­cu­lar dy­s­tro­phy, mark­ing a dis­ap­point­ing start to a string of read­outs slat­ed for the next few months.

Dubbed pam­revlum­ab, the drug is list­ed as a lead can­di­date for Fi­bro­Gen along­side rox­adu­s­tat — an ane­mia drug that’s run in­to mul­ti­ple clin­i­cal and reg­u­la­to­ry set­backs of its own. Shares $FGEN fell 9% to be­low $17 in pre-mar­ket trad­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.